Go Back   This Blue Marble, a Global Current Events Discussion Forum > Health and Medicine > Medical News

Medical News News, information and discussions about health issues, medicine and biotechnology.

 
 
Thread Tools Search this Thread Display Modes
Prev Previous Post   Next Post Next
Old 04-10-2012, 01:39 PM   #1
kaneohegirl
I LOVE Fairys too
 
kaneohegirl's Avatar
 
Join Date: Aug 2008
Location: outside KC Missouri
Posts: 3,159
Thanks: 23
Thanked 205 Times in 126 Posts
Default cure for cancer?

http://www.moneytrendsresearch.com/s...-takes-notice/

Canadian researchers find a simple cure for cancer, but major pharmaceutical companies are not interested.
Researchers at the University of Alberta, in Edmonton, Canada have recently cured cancer, yet there is but little ripple in the news or on TV. It is a simple technique using a very basic drug. The method employs dichloroacetate, which is currently used to treat metabolic disorders, so there is no concern of side effects or other long term effects.

The drug doesn’t require a patent, so anyone can employ it widely and cheaply compared to the costly cancer drugs produced by major pharmaceutical companies.



Canadian scientists tested dichloroacetate (DCA) on human cells; it killed lung, breast and brain cancer cells and left the healthy cells alone. It was tested on rats inflicted with severe tumors; their cells shrank when they were fed with water supplemented with DCA. The drug is widely available and the technique is easy to use, but why are the major drug companies not involved, or the media not interested in this find?
__________________
kaneohegirl is offline   Reply With Quote
 

Tags
cancer, cure

Thread Tools Search this Thread
Search this Thread:

Advanced Search
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -4. The time now is 10:47 PM.


Powered by vBulletin®
Copyright © Jelsoft Enterprises Ltd.